Cancer and Metastasis Reviews

, Volume 27, Issue 1, pp 85–94

The Met tyrosine kinase receptor in development and cancer

Authors

  • Alessandra Gentile
    • Division of Molecular Oncology, Institute for Cancer Research and Treatment (IRCC)University of Turin Medical School
  • Livio Trusolino
    • Division of Molecular Oncology, Institute for Cancer Research and Treatment (IRCC)University of Turin Medical School
    • Division of Molecular Oncology, Institute for Cancer Research and Treatment (IRCC)University of Turin Medical School
Article

DOI: 10.1007/s10555-007-9107-6

Cite this article as:
Gentile, A., Trusolino, L. & Comoglio, P.M. Cancer Metastasis Rev (2008) 27: 85. doi:10.1007/s10555-007-9107-6

Abstract

Met is a tyrosine kinase receptor, encoded by an oncogene, whose crucial role has been elucidated during the last two decades. The complex biological program triggered by Met has been dissected and its biological relevance in both physiology and pathology has been proven. Met supports a morphogenetic program, known as invasive growth, taking place both during embryogenesis and adulthood. In tumors Met is often aberrantly activated, giving rise to the pathological counterpart of the invasive growth program: cancer progression towards metastasis. Several approaches have been recently developed to interfere with the tumorigenic and metastatic processes triggered by Met.

Keywords

MetHGFTyrosine kinase receptorMetastasis“Invasive growth”

Copyright information

© Springer Science+Business Media, LLC 2007